Abstract. Juvenile myelomonocytic leukemia (JMML) is a rare but severe primary hemopoietic system tumor of childhood, most frequent in children 4 years and younger. There are currently no specific anticancer therapies targeting JMML, and the underlying gene expression changes have not been revealed. To define molecular targets and possible biomarkers for early diagnosis, optimal treatment, and prognosis, we conducted microarray data analysis using the Gene Expression Omnibus, and constructed protein-protein interaction networks of all differentially expressed genes. Modular bioinformatics analysis revealed four core functional modules for JMML. We analyzed the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway functions associated with these modules. Using the CMap database, nine potential anticancer drugs were identified that modulate expression levels of many JMML-associated genes. In addition, we identified possible miRNAs and transcription factors regulating these differentially expressed genes. This study defines a new research strategy for developing JMML-targeted chemotherapies.

Introduction

Juvenile myelomonocytic leukemia (JMML) is an infrequent but aggressive hematological system tumor of infancy and childhood with poor prognosis. Signs and symptoms include fever, thrombocytopenia, hemorrhage, lymphadenopathy, high fetal hemoglobin levels and progressive hematologic anemia, hepatosplenomegaly, and clonal proliferation of myelomonocytic cells (1-3). The most effective treatment currently available is allogeneic hematopoietic stem cell transplantation (HSCT). However, the overall survival at 5 years after transplant is only 52-63% due to treatment-related toxicity and frequent disease relapse (3-7). In addition, some patients lack a suitable human leukocyte antigen-matched donor, thus novel chemotherapeutic regimens are needed to further improve outcome.

Malignant tumors are a major cause of mortality in children, and traditional cancer treatments such as chemotherapy, radiotherapy and surgery carry severe side effects or do not markedly improve prognosis. As an aggressive myeloproliferative neoplasm, response to conventional chemotherapy is weak, thus most JMML patients require early allotransplantation (6,7). Alternatively, gene module analysis of JMML may facilitate the screening of anticancer drugs targeting specific anomalies in gene expression. In the present study, we performed gene module analysis to identify gene expression signatures of JMML and to illuminate the functions of these altered genes and protein networks in disease pathogenesis.

While there are voluminous studies on anticancer drug pharmacokinetics and efficacy against solid tumors, there have been few studies focusing on JMML. Drugs that target JMML-associated genes can be an effective anticancer approach, either alone or in combination with traditional modalities. Modular analysis of bioinformatic data is emerging as a valuable strategy for systematic and comprehensive analysis of regulatory signaling pathways relevant to disease etiology and drug treatment effects (8,9). In the present study, we used modular analysis bioinformatics methods to search for differentially expressed genes and their key functional group(s) and networks in JMML.

Genes differentially expressed in leukemic cells compared to normal cells were classified into upregulated and downregulated groups. These differentially expressed genes were then compared to differentially expressed genes in cells treated with small molecules from the CMap database by converting them into probe setters based on the HG-U133A platform. Genes were then assigned enrichment values between -1 and 1 according to whether specific small molecules stimulated the expression state in leukemia cells (closer to 1) or normal cells (closer to -1). Based on this analysis, we identified drugs that regulate key nodes of JMML-associated regulatory networks. The large number of genes and drugs identified provide many possible targets and effective chemotherapies for JMML.
Communicable Disease Control (12). The database provides tissue sample results from 44 JMML patients and seven healthy donors obtained using the Agilent-041648 CMGG Human V1.1 60k [Probe Name Version] microarray platform. We used the R software bagaffy (11) (Version1.50.0, http://www.bioconductor.org/packages/release/bioc/html/affy.html) to read the down-loaded microarray matrix data and the robust multi-array expression calculation. We performed annotation for probes in the platform annotation file and deleted probes that did not match the gene symbols used. When the same gene was represented by different probes, we adopted the average as the final expression value.

For the two data groups (JMML and controls), we screened for differentially expressed genes using the R bag Limma microarray analysis package (14) and adopted the BH-corrected T test to identify genes significantly over- or under-expressed. For every differentially expressed gene, we assumed a threshold P<0.05 and log2FC >0.58. Differentially expressed genes were selected based on a threshold log2FC >0.58, corresponding to a fold change >1.5 or ≤1.5 (15). We then used the common enrichment analysis tool DAVID (16) (version 6.8) and subjected genes with enrichment ≥2 and significance threshold of hypergeometric test P<0.05 to Gene Ontology (GO) (17) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) (18) pathway analyses.

For observing the function of differentially expressed genes intuitively, we used the ClueGO (19) plug-in (version 2.2.6, http://apps.cytoscape.org/apps/ClueGO) of Cytoscape software (20) and constructed separate GO BP and KEGG pathway cross-linked enrichment graphs for upregulated and downregulated genes using P<0.05 as the significantly enriched threshold.

Screening for differentially expressed genes in JMML. We downloaded JMML microarray data from the GEO platform (https://www.ncbi.nlm.nih.gov/geo/) [data code GSE71449 (human)] (10).

The criteria for data selection were gene chip expression profiling data accrued over the last three years (since 2014) with clear disease and normal control groups in the data set. The disease queried was 'Juvenile myelomonocytic leukemia'. The largest number of GSE71449 samples were obtained by such a standard. While our analysis is indeed limited to all disease-related data sets in the database, further analysis of other data sets, including miRNA chips, is already under way as no single data set represents all genes associated with a disease. The mechanisms of any disease are only revealed by direct experimental study, but these gene chip results may identify genes with greater probability of involvement. The single-chip DEG analysis can only reveal that in the current data set, these differentially expressed genes (DEGs) are most likely to be related to disease.

Array Express was retrieved, and the results retrieved with the same search criteria coincided with those in GEO. There was no larger sample size under the same screening criteria. GEO data sets are included in the EBI database, thus there is no mention of it.

The database provides tissue sample results from 44 JMML patients and seven healthy donors obtained using the Agilent-041648 CMGG Human V1.1 60k [Probe Name Version] microarray platform. We used the R software bagaffy (11) (Version1.50.0, http://www.bioconductor.org/packages/release/bioc/html/affy.html) to read the downloaded microarray matrix data and the robust multi-array average method (12,13) to perform standardized data pre-processing (including Background correction, Normalization, and Expression calculation). We performed annotation for probes in the platform annotation file and deleted probes that did not match the gene symbols used. When the same gene was reflected by different probes, we adopted the average as the final expression value.

For the two data groups (JMML and controls), we screened for differentially expressed genes using the R bag Limma microarray analysis package (14) and adopted the BH-corrected T test to identify genes significantly over- or under-expressed. For every differentially expressed gene, we assumed a threshold P<0.05 and log2FC >0.58. Differentially expressed genes were selected based on a threshold log2FC >0.58, corresponding to a fold change >1.5 or ≤1.5 (15). We then used the common enrichment analysis tool DAVID (16) (version 6.8) and subjected genes with enrichment ≥2 and significance threshold of hypergeometric test P<0.05 to Gene Ontology (GO) (17) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) (18) pathway analyses.

For observing the function of differentially expressed genes intuitively, we used the ClueGO (19) plug-in (version 2.2.6, http://apps.cytoscape.org/apps/ClueGO) of Cytoscape software (20) and constructed separate GO BP and KEGG pathway cross-linked enrichment graphs for upregulated and downregulated genes using P<0.05 as the significantly enriched threshold.

Building and analyzing modules of differentially expressed genes. We used the STRING (21) database bank to predict possible protein-protein interaction (PPI) networks for all differentially expressed proteins and genes with parameter PPI score 0.4 (medium confidence). Networks with average interaction strengths at protein nodes were constructed using Cytoscape.

Interaction networks may contain nodes in which the interactions are closed among the constituent genes. These nodes thus represent distinct biological processes. There are many methods to define nodes by PPI cluster analysis but MCODE (22) was chosen because it is the most common. We applied MCODE to calculate the scores of every node, with higher scores indicating a greater degree of separation from other nodes and stronger association with specific processes. We choose nodes with score ≥5 and node number ≥5 for subsequent GO and KEGG pathway analyses.

Screening for drugs that regulate functional modules. The CMap database (23,24) stores the genome-wide expression profiles of human cells treated with various active small molecules. In total, CMap contains data from 6,100 small molecule interference experiments (with normal control groups) using 1,309 small molecules, for a total of 7,056 different expression profiles.

We analyzed gene expression differences between normal cells and leukemia cells and then compared the responses of differentially expressed genes to identify those with similar or opposite effects (upregulation vs. downregulation) on normal cells. We divided the genes differentially expressed between normal and leukemia cells into upregulated and downregulated subgroups. Then we transformed the HG-U133A platform probe set results and compared them to the set of differentially expressed genes under small molecule treatment from the CMap database to obtain enrichment values. In this case, enrichment values range from -1 and 1, with those closer to 1 influenced to a greater extent by small molecules in normal cells and those with values closer to -1 influenced to a greater extent by small molecules in leukemia cells.

For key modular gene screening, we constructed connectivity maps and used the gene expression differences in human cells treated with small molecules to identify drugs affecting the expression levels of genes associated with the disease.

Identification of possible miRNAs regulating target genes. We identified potential miRNA targeting genes within PPIs using Webgestalt (http://www.webgestalt.org/) (25) tools and overrepresentation enrichment analysis methods with a threshold P<0.05 by hypergeometric tests and BH correction for enriched gene number and count ≥5.

Identification of possible transcription factors regulating target genes. Based on the transcription factor-regulated network data in the ITFP database and TRANSFAC bank, we searched for transcription factors regulating differentially expressed genes and further screened the differentially expressed target genes regulated by these transcription factors for network integration. We performed network integration for the obtained TF-Target, miRNA-Target, and PPI network and constructed integration networks using Cytoscape.
Statistical analysis. t-tests were used to screen for differentially expressed genes and to evaluate the enrichment obtained by GO_BP- and KEGG-based methods. A P<0.01 was considered statistically significant. With respect to each herbal component, Fisher's exact test was used to evaluate the genes in modules. Based on the above data, we set P<0.01 for each component.

Results

Screening for differentially expressed genes in JMML. We downloaded the JMML expression data from the GEO database, and identified 700 upregulated and 737 downregulated genes at threshold levels of P<0.05 and log|FC| >0.58. From these genes, we constructed heat maps (Fig. 1). We then performed GO and KEGG pathway enrichment analyses for upregulated and downregulated mRNA masure, and according to the screening threshold value obtained GO terms and KEGG pathways including these differentially expressed genes. Fig. 2A shows the top five GO Biological Process (BP) terms and KEGG pathways including upregulated mRNA and Fig. 2B shows these same results for downregulated mRNAs.

We used clueGO to perform GO and KEGG pathway analysis for all upregulated and downregulated differentially expressed genes (Fig. 3A and B). ClueGO provides kappa coefficients that can be used to divide the pathways into functional groups. In the figure, different colors indicate pathway enrichment results and correlations between two pathways are reflected by a connecting line. The sizes of nodes reflect the P-value. Fusion of enrichment results was performed when different terms were enriched for the same gene. In the figure, GO terms are indicated by different colors. Thus, one color indicates a functional group. The size of the term nodes depends on the threshold P-value, increasing as P gets smaller.

Key genes and PPI networks constructed from differentially expressed genes. Combined with the PPI database, we constructed the network figures for differentially expressed genes (Fig. 4). The PPI network of differentially expressed genes contained 908 nodes and 5,053 related pairs. The relationships among the nodes are closed. Table I lists the top 10 highest degree nodes obtained from the PPI network and Fig. 4 shows the PPI network constructed from the differentially expressed genes, with pink nodes indicating upregulated and blue nodes the downregulated genes.
Figure 2. GO and KEGG pathway enrichment analysis of the upregulated and downregulated mRNA sets. According to the screening threshold, the GO terms and KEGG pathways involving these differentially expressed genes were obtained. (A) Top five GO BP terms and KEGG pathways for upregulated mRNAs. (B) Top five GO BP terms and KEGG pathways for downregulated mRNAs. GO, Gene Ontology; BP, Biological process; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed gene.

Figure 3. The enrichment and crosslink figure of GO BP and KEGG pathways. We used clueGO to perform GO and KEGG pathway analysis for all upregulated (A) differentially expressed genes.
Modular analysis. We obtained a total of 10 modules from the PPI network, of which four had scores >3 (Fig. 5). We also performed functional enrichment analysis for the genes of modules. Fig. 6 shows the top five GO BP terms and KEGG pathways in module 1, the four KEGG pathways and top five GO BP terms in module 2, the four GO BP terms in module 3 (no KEGG pathways were enriched), and the top five GO BP terms and KEGG pathways in module 4.

For module 1, pathway analysis indicated that differentially expressed genes were most strongly (lowest P-value) related to Regulation of cell proliferation. For module 2, differentially expressed genes were most strongly related to Pathways in cancer. In module 3, the strongest relationship was with Transcription, DNA-templated, and in module 4 the strongest relationship was with Immune response.

Small drug molecules related to diseases. We performed small molecule drug analysis for the 4 modules using the CMap database and threshold P<0.05. The regulatory effects on each module are shown in Fig. 7.
Statistical relationships between modular genes and small drugs. We used local perl script and performed Pubmed searches for the analyzed modular genes and the corresponding small molecules, and constructed the network figures shown in Fig. 8. The P-values were considered in descending order, and the drugs with the 10 smallest P-values were used for subsequent analyses. A total of 40 drugs were identified as possible regulators of the 4 modules. To obtain novel anticancer drugs, we conducted a literature review of the cancer-related research on the 24 drugs with greatest effects on gene expression. In cancer treatment, the number of publications reflects the extent of research on a given drug's potential efficacy. Multiple drugs have been researched extensively and already certified to be effective anticancer drugs, such as etoposide and phosphothreonine (the number of relevant publications was >100). Others, however, have not been fully studied for their anticancer efficacies, such as disulfiram, ursolic acid, miconazole.

Table I. The top 10 highest degree nodes obtained from the PPI network.

| Gene     | Degree | Betweenness | Closeness |
|----------|--------|-------------|-----------|
| MAPK1    | 283.0  | 142874.9    | 0.54246414|
| CD4      | 218.0  | 93239.1     | 0.49266702|
| OAS3     | 212.0  | 110066.46   | 0.48373333|
| CD79A    | 173.0  | 59164.633   | 0.47862798|
| NFkBIA   | 157.0  | 37323.453   | 0.48424986|
| BCL6     | 154.0  | 42434.684   | 0.4748691 |
| EGR2     | 138.0  | 33878.51    | 0.4512438 |
| PLEK     | 134.0  | 53153.11    | 0.45509282|
| TRIB3    | 115.0  | 24556.303   | 0.44591936|
| RASLI1A  | 112.0  | 16269.245   | 0.44923228|

PPI, protein-protein interaction.
thioridazine, loperamide, monastrol (the number of relevant publications was ≤10), and others, such as nadolol, tetracaine and levomepromazine have never been studied with respect to cancer. Publication numbers for drug are shown in Fig. 9.

**Identification of candidate miRNAs regulating differentially expressed genes.** We identified candidate miRNAs that may regulate the differentially expressed genes using a screening threshold of P<0.05. For upregulated genes, we identified 10
candidate miRNAs (Table IIA) and for the downregulated genes four candidate miRNAs (Table IIB).

Identification of candidate transcription factors regulating differentially expressed genes. For the upregulated differentially expressed genes, we identified 22 differentially expressed transcription factors (TFs). For the downregulated differentially expressed genes, we identified 19 differentially expressed TFs. The results are summarized in Table III.
Figure 6. Functions of the genes in each module revealed by GO BP and KEGG analyses. (S) The top five GO BP terms and KEGG pathway results for module 1. (B) The four KEGG pathways and top five GO BP terms in module 2. (C) The four GO BP terms in module 3 (no enrichment to KEGG pathways). (D) Top five GO BP terms and KEGG pathway results in module 4. Pathways of greatest significance in each module were Regulation of cell proliferation in module 1, Pathways in cancer, Transcriptional dysregulation in cancer, and Signal transduction in module 2, Transcription, DNA-templated in module 3, and Immune response in module 4. GO, Gene Ontology; BP, Biological process; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Currently the only curative treatment option for JMML is hematopoietic stem cell transplantation (HSCT). However, disease recurrence remains a major cause of treatment failure (7). Clinical symptoms are caused by hematopoietic insufficiency and excessive proliferation of leukemic monocytes and granulocytes, leading to hepatosplenomegaly, lymphadenopathy, skin rash and respiratory failure (3,7,26). A serious obstacle to the research of JMML is the lack of suitable experimental models, impeding the development and pre-clinical evaluation of novel therapeutic approaches. Primary JMML leukemia cells cannot be maintained in culture as they differentiate and become apoptotic (27), while an immortalized cell line derived from JMML cells has not yet been successfully established (28). The generation of induced pluripotent stem cell lines originating from JMML cells was reported, but conceptually such systems are limited by their artificial nature and the risk of further transformation during reprogramming (29). Therefore, it is important to identify tumor-promoting processes, such as dysregulation of specific genes and networks, and develop targeted therapies.

In the present study, we combined the genome-wide gene chip information already available from JMML tissues and used modular analysis bioinformatics procedures to identify molecular targets and small molecule compounds that affect their expression. For this purpose, modular analysis is a valuable and well established bioinformatic method that is useful...
Figure 8. We used local perl script and performed Pubmed searches for each small molecule, and constructed network figures (Pink genes in module 1, red genes in module 2, purple genes in module 3, and yellow genes in module 4). Arrows represent small molecule drug regulatory relationships. The line thickness represents the volume of existing research on these small molecule drugs and genes, with thicker lines indicating more extensive research (more publications). Blue V indicates small molecule drugs.

Figure 9. To evaluate potential efficacy, we conducted a literature appraisal of 24 small molecules. The number of publications is indicative of the extent of study on cancer. Those with fewer publications may be novel anticancer drugs. Of those identified, many are confirmed to be anticancer drugs, for example etoposide and phosphonothreonine (>100 relevant publications), while others have not been studied extensively for anticancer efficacy, for example disulfiram, ursolic acid, miconazole, thioridazine, loperamide and monastrol (≤10 relevant publications). A few, such as nadolol, tetracaine, and levomepromazine, have never been examined for anticancer properties.
for analysis of both large-scale protein networks and single proteins and genes. Moreover, this method has been used to study the development and treatment of multiple diseases. After the enrichment analysis, we found that genes related to the hematopoietic cell lineage and to regulation of immune responses were significantly downregulated, while chemokine signaling pathway and inflammatory response genes were significantly upregulated compared to healthy tissue.

Hematopoietic progenitors produce a myriad of diverse lineages, including progenitors with lymphoid, myeloid, and erythroid potential, prior to hematopoietic stem cells. Previous pathway analyses revealed that genes related to hematopoietic cell lineages were significantly downregulated in JMML (30-34), and we further found that genes related to regulation of immune responses were also significantly downregulated. Anticancer treatment leads to dense immune infiltrate, including many CD8+ and CD4+ cells, concomitant with tumor regression, at both treated and untreated lesions, consistent with generation of a tumor-specific systemic immune response (35). Several studies have indicated the synergistic potential of various immunomodulatory agents (36-39). Therapies that enhance or impede immune responses are essential but optimal timing and the administration route are important determining results, such as increased survival and immune responses, leading to complete tumor regression in some cases (40-42).

Ruminants of efficacy. Preclinical studies combining these agents have shown proThe PI3K/Akt and MAPK signaling pathways have been shown to mediate chemokine-induced migration of multiple cell types. Modular analysis suggested that the Chemokine signaling pathway (module 1) was strongly related to JMML morbidity. In addition to regulation of cell proliferation, differentiation, invasion, and inflammation, chemokines are widely involved in the regulation of cancer. Analysis of module 1 revealed that regulation of cell proliferation was significantly increased and strongly related to JMML occurrence. Further, analysis of all 4 functional modules revealed complex interactions among a number of genes involved in Chemokine signaling pathway and Regulation of cell proliferation. Chemokines are small proteins expressed in response to injury or infection and during normal immune surveillance. Chemokines involved in leukocyte trafficking and regulate tumor metastasis, proliferation, differentiation and angiogenesis (43-46).

Module 2 contained genes primarily involved in Pathways in cancer, Transcriptional dysregulation in cancer, and Signal transduction, suggesting that module 2 contains clusters of key tumor-promoting genes. Accumulation of driver somatic alterations in genes modifies critical cellular processes leading to cancer (47,48). In recent years, the catalog of driver genes known to take part in the development of malignancies has expanded due to whole-exome and whole-genome analyses of large tumor sets by large international consortia (49,50). In addition to upregulation of oncogenes, downregulation of anticancer proteins or dysregulation of subcellular localization may also contribute to JMML.

Cancer cells scatter from tumors in hoards and build new tumors in distant tissues and organs (51,52). In over 90% of fatal cancers, metastasis is the cause of death. Tumors contain a heterogeneous population of cells in an organized hierarchy akin to normal tissue. Tumor progression, invasiveness, and self-renewal are attributes of smaller subfractions of cancer cells. Tumor initiation by disseminated cancer cells relies on their ability to self-renew and initiate metastatic tumors.

Genes in module 3 were primarily involved in Response to hypoxia. Negative regulation of transcription from RNA polymerase II promoter, Regulation of transcription, DNA-templated, and Transcription, DNA-templated. We found that among these pathways, transcription, DNA-templated was most strongly related to JMML occurrence. The identification and detection of specific nucleic acids (either DNA or RNA) is an enabling technology for forensic analysis (53), recognition of genetic mutations (54) and pathogen identification (55). For many methods, quantification of nucleic acids is important for identifying a given DNA sequence. For example, in many forms of cancer (56), oncogene copy number increases and deletion of tumor-suppressor genes can be found. In addition to measuring changes in gene copy number, quantitative detection of circulating DNAs can be a useful diagnostic tool for identifying cancer (57).

The genes in module 4 are closely associated with extracellular matrix organization and immune responses. Much effort has been devoted to determining how cellular components of the tumor promote cancer development and initiate formation of a niche conducive to growth (58). Alternatively, the importance of non-cellular components of the niche during cancer progression is well documented, particularly extracellular matrix (ECM) organization (59-62). In addition to a stable structure with supportive functions in maintaining tissue morphology, the ECM is a surprisingly dynamic and versatile part of the cell milieu influencing fundamental aspects of cell biology (63). For major developmental processes, the ECM directly or indirectly regulates almost all cellular behaviors (64-67). Indeed, in diseases such as cancer, abnormal ECM dynamics may be a strong determinant of clinical outcome (68). How disruption of ECM dynamics contributes to tumor development is a challenging issue in cancer biology.
The local immune response has also emerged as an important element in the multistep process of cancer development (69). Observations that some tumors arise from chronic inflammation sites have led to speculation of a strong connection between tumor onset and inflammatory pathways. In addition, some tumors are infiltrated by both the innate and adaptive arms of the immune system, thus many different immune cells are present within the tumor micro-environment (70). Elements of both the innate and adaptive immune systems have been reported to act both as pro- or anti-tumorigenic factors depending on the relative balance. The intercellular communication between infiltrating immune cells and cancer cells modulates this immune response so as to positively influence tumor development (71).

We found the module 2 was most strongly related to JMML occurrence. There are likely synergistic interactions among module 2 genes.

Many investigations have attempted to screen for well-tolerated and affordable anti-neoplastic medications, and a myriad of drugs with cytotoxicity against human cancer cell lines have been described (72,73). In our study, we also screened for drugs with curative potential against JMML through modulation of associated gene pathways. In 1999, Mayer et al (74) first identified monastrol, a cell-permeable small molecule with antimitotic activity but without neuronal cytotoxicity. Through inhibition of kinesin Eg5, monastrol can induce the mono-astral conformation of microtubules (75,76). Several subsequent studies have clarified the anti-mitotic mechanisms of monastrol (77-79), but few studies have investigated its anticancer activity (80-82).

In both canine and human cancer patients, the peripherally acting µ-opiate receptor agonist loperamide hydrochloride is recommended as a treatment for chemotheraphy-related diarrhea (83,84). Loperamide was shown to dose-dependently induce apoptosis and suppress the proliferation of human liver, lung, bone, and breast cancer cell lines (85). In human cancer cell lines, the mechanism underlying apoptosis induction has not been fully elucidated, although the caspase 3 pathway has been implicated (85) and loperamide will exert anticancer properties at clinically relevant doses. In the clinic, loperamide would be an attractive drug for JMML because of its minimal side effects and low price. Our bioinformatic analysis revealed a potential role for loperamide in JMML treatment. Further studies are needed to establish mechanisms of antitumor activity.

Originally, thioridazine (TDZ) was used as a therapy for psychotic disease (86,87). In addition, it has been used to treat drug-resistant microorganisms (88,89). Recently TDZ was reported to have potent effects on various types of cancer cells, including anti-angiogenesis and apoptosis promotion of breast and ovarian cancers cells (90,91). In addition, TDZ induced cytotoxicity of cervical (92), prostate (93), gastric (94), and pancreatic cancer cells (95). TDZ also has selectivity in leukemia as a dopamine receptor inhibitor (96,97).

A few publications have suggested that miconazole has anticancer effects (98). Miconazole is a common treatment for superficial fungal infection and a prominent systemic anti-fungal agent. In different human neoplastic cell lines, Wu et al demonstrated that miconazole could induce cell cycle arrest. This growth arrest was dose-dependent and related to the p53 signaling pathway (99). Anticancer effects of miconazole were reported on 4T1 (breast cancer) and 5637 (bladder cancer) cell lines.

Ursolic acid (UA) was found to have a biphasic response against three breast cancer cell lines (100). Another study (101) reported that disulfiram suppressed tumor growth by killing cancer cells and was even effective in combination with DHA. Indeed, UA could act as a substitute for clioquinol.

Compared to treatments targeting individual genes, treatment with agents affecting larger gene groups may have better efficacy as anticancer therapy. The aim of the present research was to identify possible molecular targets for cancer treatment and potential anticancer drugs. We searched for drugs that regulate the essential functional modules of JMML using the DrugBank Small Molecule database, and found several drugs already shown to have anticancer effects, including nadolol, disulfiram, urso acid, miconazole, thioridazine, loperamide, monastrol, tetracaine, and levomepromazine. In contrast, other drugs identified have never been examined for anticancer efficacy, such as tetracaine, levomepromazine and nadolol. Nonetheless, effects on differentially expressed genes in JMML suggest therapeutic potential.

The nine drugs identified are potential therapies for JMML. Many widely used and studied drugs have never been examined for effects against cancer, such as tetracaine, levomepromazine and nadolol. According to our enrichment analyses, these agents hold potential for JMML treatment. We searched the Pubmed database and found several RCTs on these drugs, but no published clinical RCTs supporting anticancer effects on JMML. In the future, we plan to perform RCTs on these nine drugs examining possible therapeutic efficacy against JMML.

When designing therapeutic regimens for JMML, possible adverse reactions must be considered. It is thus noteworthy that the drugs identified here are in clinical use with well described safety profiles. When tumor cell proliferation reaches the highest activity, drugs interfering with the cell cycle or targeting proliferation pathways are significantly more potent.

MicroRNAs are endogenous 20-25 nucleotide non-coding RNAs found in eukaryotes that regulate gene expression at the level of translation. Mature miRNAs are produced by sequential cleavage of longer primary transcripts. Then the RNA-induced silencing complex RISC induced by RNA is assembled to recognize target mRNAs by base complementary pairing, and the target mRNA is degraded or suppressed according to the degree of complementarity. Recent studies have shown that the silencing complex degrades the target mRNA or inhibits the translation of the target mRNA. Through gene silencing, miRNAs regulate diverse processes including growth, virus defense, hematopoiesis, organ formation, cell propagation, apoptosis, and fat metabolism, among others. Transcription factors (TFs) are proteins with special structures that regulate gene expression at the level of the genome. The transcription initiation of eukaryotes is complex and requires the assistance of multiple protein cofactors. Transcription factors form a transcription initiation complex with RNA polymerase II. Both miRNAs and TFs regulate genes, thus differentially expressed genes (DEGs) are predicted by miRNAs and TFs, which further extends the number of potential targets. Like differentially expressed genes, the prediction of miRNAs and
TFs involved in differential expression also provides clues to disease mechanisms.

In conclusion, our study used multiple bioinformatic methods to identify 4 gene modules associated with JMML. In addition, we identified 40 drugs based on the CMap database that can alter expression and function of the 4 modules. We performed Fisher's exact test to precisely screen for drugs with the strongest effects on module regulation. Through our study, we identified nine drugs that have considerable potential as new anticancer drugs. Moreover, the study provides a new research template for future research on JMML-targeted anticancer treatments through detailed analyses of core functions. In the future, we will conduct follow-up studies to verify the anticancer effects of the selected drugs.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Research Project of Heilongjiang Health and Family Planning Commission (project no. 2016-038).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

WZ and YY conceived and designed the study. WZ, LW and YY performed the experiments. WZ, LW and YY wrote the manuscript. WZ and LW and YY reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Chan RJ, Cooper T, Kratz CP, Weiss B and Loh ML: Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium. Leuk Res 33: 355-362, 2009.
2. Niemeyer CM and Kratz CP: Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: Molecular classification and treatment options. Br J Haematol 140: 610-624, 2008.
3. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Haas O, Harbott J, Hasle H, Kernndrup G, et al: Chronic myelomonocytic leukemia in childhood: A retrospective analysis of 110 cases. European working group on myelodysplastic syndromes in childhood (EWOG-MDS). Blood 89: 3534-3543, 1997.
4. Bergstraesser E, Hasle H, Rogge T, Fischer A, Zimmermann M, Noellke P and Niemeyer CM: Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia. A retrospective analysis and definition of response criteria. Pediatr Blood Cancer 49: 629-633, 2007.
5. Dvorak CC and Loh ML: Juvenile myelomonocytic leukemia: Molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Front Pediatr 2: 25, 2014.
6. Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfil CS, et al: Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOGMDS/EBMT trial. Blood 105: 410-419, 2005.
7. Locatelli F and Niemeyer CM: How I treat juvenile myelomonocytic leukemia. Blood 125: 1083-1090, 2015.
8. Wang PI and Marcotte EM: It’s the machine that matters: Predicting gene function and phenotype from protein networks. J Proteomics 73: 2277-2289, 2010.
9. Hedges SB: The origin and evolution of model organisms. Nat Rev Genet 3: 838-849, 2002.
10. Helsmoortel HH: Gene expression profiling of 44 JMML patients and 7 healthy donors (discovery cohort). Homo sapiens. Dec 23, 2015.
11. Gautier, L, Cope L, Bolstad BM and Irizarry RA: Abyg-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315, 2004.
12. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformaticis 19: 185-193, 2003.
13. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.
14. Smyth GK, Limma: Linear models for microarray data, in Bioinformatics and computational biology solutions using R and Bioconductor. Springer. 397-420, 2005.
15. Liu H, Xu R, Liu X, Sun R and Wang Q: Bioinformatic analysis of gene expression in peripheral blood mononuclear cells from children with type 1 diabetes in 3 periods. Exp Clin Endocrinol Diabetes 122: 477-483, 2014.
16. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2008.
17. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene Ontology: Tool for the unification of biology. Nat Genet 25: 25-29, 2000.
18. Kanehsa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
19. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene Ontology: Tool for the unification of biology. Nat Genet 25: 25-29, 2000.
20. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene Ontology: Tool for the unification of biology. Nat Genet 25: 25-29, 2000.
21. Kandelisa H and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
22. Kandelisa H and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
23. Kandelisa H and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
24. Kandelisa H and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
31. Gualtieri RJ, Castleberry RP, Gibbons J, Miller DM, Berkow RL, McNeel DG, Chen YH, Gulley JL.

32. Yoshimoto M, Montecino-Rodriguez E, Ferkowicz MJ, Sakashita K, Kato I, Daifu T, Saida S, Hiramatsu H, Nishinaka Y, Chang TY, Dvorak CC and Loh ML: Bedside to bench in juvenile hematopoiesis during development. Blood 104: 3097-3105, 2004.

33. Hadland BK, Huppert SS, Kanungo J, Xue Y, Jiang R, Gridley T, Tang N and McCart J: Intratumoral recombinant gm-csf-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Therapy 13: 189-200, 2006.

34. Yoder MC and DiPaola RS: Randomized phase II trial of Poxvirus-based active immunotherapy with PD-1 and LAG-3 for patients with cutaneous melanoma. Cancer Immunol Immunother 65: 701-713, 2016.

35. Ben-Baruch A: The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 25: 357-371, 2006.

36. Luther SA and Cyster JG: Chemokines as regulators of T cell differentiation. Nat Immunol 2: 102-107, 2001.

37. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.

38. Vogelzang B, Papadopoulos N, Velucosele VC, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science 339: 1546-1553, 2013.

39. Cancer Genome Atlas Research Network; Weinstein JN, Collisson EA, Mills GB, Shew KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome atlas pan-cancer analysis project. Nat Genet 45: 1113-1120, 2013.

40. International Cancer Genome Consortium: Henderson-Tate DJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS et al: International network of cancer genome projects. Nature 464: 993-998, 2010.

41. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coomes RC, Schlimok G, Dierl J, Gerber G, Gebauer G et al: A pooled analysis of bone metastasis and metastasis in breast cancer. N Engl J Med 353: 793-802, 2005.

42. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstorf J, Borgen E, Rack B, Braun S, Sommer H et al: Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin Cancer Res 17: 2967-2976, 2011.

43. Budowle B, Allard MW, Wilson MR and Chakraborty R: Forensics and mitochondrial DNA: Applications, debates, and foundations. Ann Rev Genet 4: 119-140, 2003.

44. International HapMap Consortium; Frazer KA, Ballingger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JWM, Boudreau A, Hardenbol P, Leal SM et al: A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861, 2007.

45. Cheng X, Chen G and Rodriguez WR: Micro-and nanotechnology for viral detection. Anal Bioanal Chem 393: 487-501, 2009.

46. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kao WL, Chen Z, Zhai Y et al: High-resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20: 207-211, 1998.

47. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA and Tavecchio L: Analysis of circulating tumor DNA in plasma at the disease during follow-up of lung cancer patients. Cancer Res 61: 4675-4678, 2001.

48. Bhowmick NA, Neilson EG and Moses HL: 2004. Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004.

49. Bissell MJ, Soloway P, Itohara S and Werb Z: Extracellular matrix: Not just pretty fibrils. Trends Cell Biol 13: 891-906, 2003.

50. Marstrand JG, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatch AJ and Latteme EC: Intratumoral recombinant gm-csf-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422, 1999.

51. Meenel DG, Chen YH, Gullel JL, Dwyer AJ, Madan RA, Carducci MA and DiPaola RS: Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-AACR nurse cancer research group (E1809). Hum Immunol 61: 733-739, 2004.

52. Outtore-Perry K, Acuna SA, Angarita FA, Sellers C, Zerhouni E, Qian N and McArthur MA: Oncolytic vaccinia virus synergizes with tritotecan in colorectal cancer. Mol Oncol 5: 159-162, 2011.

53. Quemard D, Zaidi A, Moreau G, Picard F, Courtoy P, Pouy b, Gervais R, Oette R, Szasz S, Kazarovac A, et al: TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (time): Results from the phase IIb part of a randomised, double-blind, placebo-controlled, phase 2B3 trial. Lancet Oncol 17: 212-223, 2016.

54. Foy SP, Sennino B, dela Cruz T, Cote JJ, Gordon EJ, Kemp F, Xavier V, Franszuzoof A, Rountree RB and Mandl SJ: PVX-based active immunotherapy with PD-1 and LAG-3 dual immune checkpoint inhibition overcomes compensatory immune regulation, yielding complete tumor regression in mice. PLoS One 11-e0150084, 2016.

55. Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franszuzoof A and Rountree RB: PVX-based active immunotherapy synergizes with CTLA-4 blockade in a mouse tumor model by improving the magnitude and quality of cytotoxic T-cells. Cancer Immunol Immunother 65: 537-549, 2016.

56. Cappuccini F, Stirrbing S, Pollock E, Hill AV and Redchenko I: Immunogenicity and efficacy of the novel cancer vaccine based on simian adeno virus and MVA vectors alone and in combination with PD-1+ and OX40L in a mouse model of prostate cancer. Cancer Immunol Immunother 65: 701-713, 2016.
65. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P and Werb Z: Altered endochondral bone development in matrix metalloprotease 13-deficient mice. Development 131: 5883-5895, 2004.

66. Rebustini IT, Myers C, Lassiter KS, Surmack A, Szabova L, Holmbeck K, Pedchenko V, Hudson BG and Hoffman MP: MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Dev Cell 17: 482-493, 2009.

67. Lu P, Takai K, Weaver VM and Werb Z: Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 3: a005085, 2011.

68. Cox TR and Ehrler JT: Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer. Dis Model Mech 4: 165-178, 2011.

69. Kitamura T, Qian BZ and Pollard JW: Immune cell promotion of metastasis. Nat Rev Immunol 15: 73-86, 2015.

70. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.

71. DeNardo DG and Coughans LM: Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9: 212, 2007.

72. Hatzoglou A, Ouafik L, Bakogeorgou E, Thermos K and Holmbeck K, Pedchenko V, Hudson BG and Hoffman MP: MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Dev Cell 17: 482-493, 2009.

73. Crews CM and Mohan R: Small-molecule inhibitors of the cell surface proteinase 13 in human glioblastoma cells. 2. J Med Chem 35: 687-694, 1992.

74. Liu X, Gong H and Huang K: Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci 104: 651-656, 2013.

75. Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, et al: Pharmacologic inhibition of MALTI protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBC. Cancer Cell 22: 825-837, 2012.

76. Sachlos E, Risueño RM, Lorande S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, et al: Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149: 1284-1297, 2012.

77. Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick JL and Yang YY: Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 35: 1096-1108, 2014.

78. Nudelman A, Ruse M, Aviram A, Rabizadeh E, Shaklai M, Zimrah Y and Rephaeli A: Novel anticancer prodrugs of butyric acid. J Med Chem 35: 687-694, 1992.

79. Wu CH, Jeng JH, Wang YJ, Tseng CJ, Liang YC, Chen CH, Lee HM, Lin JK, Lin CH, Lin SY, et al: Antitumor effects of thioridazine stereoisomers on the drug accumulation of cancer cells. Arch Biochem Biophys 465: 166-1684, 2005.

80. Yang YY: Co-delivery of thioridazine and disulfiram act in concert to kill ovarian cancer xenografts. Oncotarget 5: 4929-4934, 2014.

81. ZHAO et al: GENE MODULE ANALYSIS OF JUVENILE MYELOMONOCYTIC LEUKEMIA...